As IL-17+ MCs were significantly associated with CIS, a lesion with a poor prognosis, we anticipated that increased numbers of these cells would be associated with poorer outcome, an association recently observed in gastric cancer [23]. The gene discussed is IL17A; the disease is in situ carcinoma.